Conatumumab
Information
- Drug Name
- Conatumumab
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| Ewing sarcoma of bone | CASP8 EXPRESSION CASP8 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 26291055 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In-vitro and in-vivo sensitivity to DR5 antibody c... | CASP8 | CASP8 EXPRESSION CASP8 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00630786 | Completed | Phase 1/Phase 2 | Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study | January 2008 | November 2010 |
| NCT01327612 | Completed | Phase 2 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | March 3, 2011 | February 5, 2020 |
| NCT01940172 | Completed | Phase 1 | Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer | November 2013 | December 2015 |
| NCT01017822 | Withdrawn | Phase 1/Phase 2 | Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer |